Intravenous therapy Intravenous licence EU Avastin licence US BevacizumabBevacizumab ... cancer, and eye disease. Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial ... Target practice lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced .... Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Citation needed date August 2010 Bevacizumab is currently approved by the Food and Drug Administration ... Nixes Bevacizumab for Breast Cancer author http www.medpagetoday.com MedPageToday date 2010 07 ... in April 2009 found that bevacizumab is not effective at preventing recurrences of non metastatic colon ... 12414204ABC news ref Background Bevacizumab is a humanized monoclonal antibody , and was the first commercially ... cancer Bevacizumab was approved by the FDA in February 2004 for use in metastatic colorectal cancer ... addition of bevacizumab to oxaliplatin 5 FU leucovorin FOLFOX4 therapy. It was approved by the EMEA ... data shows that bevacizumab has no effect on survival but has been shown to improve Progression ... bevacizumab for use in lung cancer in combination with standard first line chemotherapy. A study conducted ... unfortunately not mirrored this finding, and overall data shows that bevacizumab has no effect on survival ... NCCN Guidelines for Breast Cancer to affirm the recommendation regarding the use of bevacizumab ... Bevacizumab for use in breast cancer . A panel of outside advisers voted 5 to 4 against approval ... benchmarks for late stage cancer treatments. The clinical trial did show that bevacizumab reduced tumor ... Commission approved bevacizumab in combination with paclitaxel for the first line treatment of metastatic ... German ref Other cancers In certain renal kidney cancers, Bevacizumab improves the progression free survival time but not survival time. In 2009, the FDA approved Bevacizumab for use in metastatic ... and EU approval in 2007. Also in 2009, an FDA advisory committee unanimously recommended Bevacizumab ... more details
Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W title Bevacizumab ... to get them to use more ranibizumab rather than their less expensive bevacizumab, in anticipation ... and bevacizumab to assess the relative safety and effectiveness in treating ARMD. Some retina specialists consider the tactic bribery. In 2008, bevacizumab cost Medicare only 20 million for about ... showed no superior effect of ranibizumab versus bevacizumab in direct comparison. ref cite doi 10.1038 ... more details
with one such drug, Bevacizumab , may be effective in treating lymphangiosarcoma. ref .... An open label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. Northwestern ..., TX ref Investigation of bevacizumab in combination with other chemotherapy agents is underway. See ... more details
refimprove date January 2009 Napoleone Ferrara , M.D. , Ph.D. is an Italian American molecular biologist and is currently a Genentech Fellow in tumor biology and angiogenesis. He is credited with identifying the human Vascular endothelial growth factor VEGF gene and describing its angiogenesis proangiogenic properties, which formed the basis for the development of Genentech s bevacizumab and Lucentis monoclonal antibody treatments. For his VEGF discovery, he won a Lasker Award in 2010. ref cite web url http www.laskerfoundation.org awards 2010 c description.htm title 2010 Winners Lasker DeBakey Clinical Medical Research Award author Strauss, Evelyn publisher The Lasker Foundation accessdate 2010 11 11 ref Education Dr. Ferrara received his medical degree from the Facolt di Medicina e Chirurgia dell Universit di Catania University of Catania Medical School in Italy in 1981, and joined Genentech in 1988. ref http www.sciencedirect.com science? ob ArticleURL& udi B6T64 4FYG6N7 5& user 4429& rdoc 1& fmt & orig search& sort d&view c& acct C000059602& version 1& urlVersion 0& userid 4429&md5 0c53e7083cf75f478bba859312458ba4 Napoleone Ferrara discusses Avastin and the future of anti angiogenesis therapy , ScienceDirect. ref References reflist Persondata Metadata see Wikipedia Persondata . NAME Ferrara, Napoleone ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Ferrara, Napoleone Category Year of birth missing living people Category Living people Category Italian scientists Category Molecular biologists italy biologist stub ... more details
for the treatment of cancer . The first anti VEGF drug, a monoclonal antibody named bevacizumab , was approved in 2004. Approximately 10 15 of patients benefit from bevacizumab therapy however, biomarkers for bevacizumab efficacy are not yet known. Current studies show that VEGFs are not the only promoters ... monoclonal antibodies such as bevacizumab Avastin , antibody derivatives such as ranibizumab Lucentis ... url pmc 2847675 ref Ranibizumab vs. Bevacizumab for Treating Neovascular Age related Macular Degeneration Ranibizumab , a monoclonal antibody fragment Fab derived from bevacizumab , has been developed ... to high cost, many ophthalmologists have turned to bevacizumab as the alternative intravitreal agent ... effective the bevacizumab, ranibizumab is not cost effective. It was concluded that the price of ranibizumab ... S. C. last5 Lotery first5 A. title Ranibizumab Lucentis versus bevacizumab Avastin modelling cost ... 17431015 pmc 1954941 doi 10.1136 bjo.2007.116616 ref Off label use of intravitreal bevacizumab has ... uses, some studies suggest that bevacizumab is effective in increasing visual acuity with low ... Institutes of Health NIH announced that it would fund a comparative study trial of ranibizumab and bevacizumab ... more details
510 in patients with advanced cancer. J Clin Oncol 23 22 5188 97 ref . The combination of bevacizumab ... M, Geier D, Nixon A, Howard L, Evans D, Li H, Hurwitz H. 2007 A phase I study of bevacizumab BV ... more details
unreferenced date June 2010 Infobox Disease Name PAGENAME Image Caption DiseasesDB ICD10 ICD10 J 34 8 j 30 ICD9 ICD9 478.1 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID A nasal septum perforation is a medical condition in which the nasal septum , the cartilage cartilaginous membrane dividing the nostrils , develops a hole or fissure. This may be brought on directly, as in the case of nasal body piercing piercing s, or indirectly, as by long term topical drug use like cocaine or decongestant nasal sprays, chronic nosebleed epistaxis , aggressive digital nasal cleaning nose picking and as a complication of nasal surgery like septoplasty or rhinoplasty . Much less common causes for perforated nasal septums include rare granulomatous inflammatory conditions like Wegener s granulomatosis . It has been reported as a side effect of anti angiogenesis drugs like bevacizumab . Symptoms A perforated septum can vary in size and location, and is usually found deep inside the nose. It may be asymptomatic, or cause a variety of symptoms. Small perforations can cause a whistling noise when breathing. Larger perforations usually have more severe symptoms. These can be a combination of crusting, blood discharge, difficulty breathing, nasal pressure and discomfort. The closer the perforation is to the nostrils, the more likely it is to cause symptoms. Treatment The majority of septal perforations can be managed without surgery. The hole will never close but if the open, raw trailing edge of the perforation can heal, the vast majority of symptoms resolve. The open irritated and raw surface must be continuously covered with a cream using a cotton applicator. This will prevent this area from drying out, cracking, bleeding, forming a scab and crusting up. A few months of successful application will allow the ulcerated edge to heal and reduces or resolves symptoms. In a small percentage of patients surgery is necessary to alleviate symptoms. There are several different surgical ... more details
Infobox Disease Name Rubeosis iridis Image Caption DiseasesDB 11743 ICD10 ICD10 H 21 1 h 15 ICD9 ICD9 364.42 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID Rubeosis iridis is a medical condition of the Iris anatomy iris of the eye in which new abnormal blood vessel s i.e. neovascularization are found on the surface of the iris. ref DorlandsDict seven 000093827 rubeosis iridis ref Pathophysiology It is usually associated with disease processes in the retina , which involve the retina becoming starved of oxygen ischaemic . The ischemic retina releases a variety of factors, the most important of which is VEGF. These factors stimulate the formation of new blood vessels angiogenesis . Unfortunately, these new vessels do not have the same characteristics as the blood vessels originally formed in the eye. In addition, new blood vessels can form in areas that do not have them. Specifically, new blood vessels can be observed on the iris. In addition to the blood vessels in the iris, they can grow into the angle of the eye. These blood vessels then block fluid leaving the eye and result in an increase in intraocular pressure. This is called neovascular glaucoma . Treatment If caught early, the neovascularization can be reversed with prompt pan retinal photocoagulation PRP , or injection of anti VEGF medications with subsequent PRP. The injection blocks the direct effect of VEGF and acts more quickly but will wear off in about 6 weeks. ref Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab Avastin injection. Retina. 2006 Mar 26 3 354 6. PMID 16508439. ref PRP has a slower onset of action but can last permanently. Once the neovascularization has been longstanding, the new vessels recruit fibrous tissue, and as this forms and contracts, the angle can be permanently damaged, and will not respond to treatment. If this occurs, then surgical intervention is required to reduce the pressure such as a glaucoma drainage implant C ... more details
attendant surgical risks and generally poor outcomes. Intravitreal injection of bevacizumab Avastin ... bevacizumab Avastin for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity ... doi 10.4103 0301 4738.29505 ref In a recent clinical trial comparing bevacizumab with conventional laser therapy, intravitreal bevacizumab monotherapy showed a significant benefit for zone I but not zone ... more details
the cancer drug Bevacizumab commercial name Avastin to treat 10 patients with neurofibromatosis type ... with bevacizumab, tumours shrank in 9 of them, with the median best response rate of 26 . Hearing improved .... Bevacizumab works by cutting the blood supply to the tumours and thus depriving them of their growth ... cgi content full 12 1 14 ref Overall the researchers believed that bevacizumab showed clinically ... of bevacizumab can be established in NF2 patients. Management of Hearing Loss in NF2 Because hearing ... more details
about side effects in the context of medicine side effects in the context of computer science Side effect computer science In medicine , a side effect is an effect, whether therapeutic or adverse, that is secondary to the one intended although the term is predominantly employed to describe adverse effect s, it can also apply to beneficial, but unintended, consequences of the use of a drug . Occasionally, drugs are prescribed or procedures performed specifically for their side effects in that case, said side effect ceases to be a side effect, and is now an intended effect. For instance, X ray s were historically and are currently used as an imaging technique the discovery of their oncolytic capability led to their employ in radiotherapy ablation of malignancy malignant tumour s. Use of drugs for unapproved indications that is, for their side effects is termed off label use . For instance, opioids, which are approved as palliative care palliative treatment for pain , may also be used for their euphoriant properties as anxiolytics or antidepressants , whether medically or recreational drug use recreationally . Off label use of drugs, although similar in meaning to side effects, is not to be confused with them side effects describe the mechanism of action that a drug used off label takes, whereas off label use implies the desired consequences of using a drug for its side effects. Off label use of drugs is legal the manner in which prescription medication is to be used is solely at the discretion of the physician prescriber . However, the marketing of drugs towards unapproved indications is illegal in fact, several pharmaceutical development firms have been fined for unapproved promotion of their products, notably Cephalon with Actiq , a sublingual fentanyl formulation, in September 2008. ref http www.usdoj.gov archive opa pr 2008 September 08 civ 860.html ref Examples of therapeutic side effects Bevacizumab Avastin has been used against wet age related macular degenerat ... more details
Preferential hyperacuity perimetry is a psychophysical test used to identify and quantify visual abnormalities such as metamorphopsia and scotoma. Background Vision abnormalities such as metamorphopsia distortions and scotoma are symptoms of retinal diseases such as Macular degeneration . In advanced stages of the disease, photoreceptor cell s may be irreversibly damaged. Hence,if not treated Macular degeneration may lead to blindness. Awareness to early changes in vision, especially in high risk patients, leads to early treatment such as intravitreal injection of anti VEGF factors, e.g. bevacizumab or ranibizumab and prevents loss of vision ref cite journal author Loewenstein A. title The significance of early detection of age related macular degeneration Richard & Hinda Rosenthal Foundation lecture. journal Retina. date September 2007 volume 27 issue 7 pages 873 878 pmid 17891011 ref . Because of complex brain mechanisms such as Filling in , patients with small and peripheral defects in their vision are often unaware of such changes until late stages in the disease ref cite journal author Achard OD, Safran AB, Duret FC, Ragama E. title Role of the completion phenomenon in the evaluation of Amsler grid results journal Am J Ophthlamol. date September 1995 volume 20 issue 3 pages 322 329 pmid 7661204 ref . Another problem is that minute visual aberrations can be normal and therefore should be distinguished from genuine visual abnormalities. Preferential hyperacuity perimetry PHP is a technology that bypasses Filling in and quantifies the extent of visual abnormalities ref cite journal author Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schahat AP, Bressler NM, Bressler SB, Conney MJ, Alster Y, Rafaeli O, Malach R. title Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age related macular degeneration . journal Retina. date April May 2005 volume 25 issue 3 pages 296 303 pmid ... more details
have tried bevacizumab Avastin , a monoclonal antibody directed against VEGF. While some reports were .... title Treatment of POEMS syndrome with bevacizumab journal Haematologica volume 92 issue 10 pages ... more details
Known inhibitors include the drug bevacizumab which binds vascular endothelial growth factor VEGF ... br use in Mechanism bevacizumab Cancer binds vascular endothelial growth factor VEGF carboxyamidotriazole ... more details
4 pages 214 6 year 2006 month September pmid 16767537 doi 10.1007 s10194 006 0291 5 url ref or bevacizumab ... M title Splenic infarction and bevacizumab journal Lancet Oncol. volume 7 issue 12 pages 1038 year ... more details
Bevacizumab Avastin 2004 humanized vascular endothelial growth factor colorectal cancer Cetuximab ... journal J Clin Oncol volume 20 issue 1 pages 205 213 pmid 11773171 ref BevacizumabBevacizumab is a humanized ... . Bevacizumab is indicated for colon cancer but has been applied to numerous other cancers in small scale studies, especially renal cell carcinoma . Results obtained showed that bevacizumab increased ... J last8 Baron first8 A last9 Griffing first9 S title Bevacizumab plus irinotecan, fluorouracil, and leucovorin ... more details
chemoradiotherapy, antiangiogenic therapy with bevacizumab , gamma knife radiosurgery, and symptomatic ... Administration approved Avastin bevacizumab to treat patients with glioblastoma at progression ... Brain Cancer ref Unlike the case for colon cancer, lung cancer and other cancers where bevacizumab ... of chemotherapy to bevacizumab did not improve on results from bevacizumab alone. Bevacizumab ..., and both may coexist. Both respond to bevacizumab. Gene transfer Gene transfer is a promising approach ... more details
molecular therapy with VEGF blocking monoclonal antibodies such as bevacizumab may be active ... RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin ... A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel carboplatin alone or with bevacizumab ... plus gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non ... comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously ... more details
K, Wang YJ, Chen XR, Chen HN title Effectiveness and safety of bevacizumab for unresectable non small ... year 2010 pmid 20225906 doi 10.2165 11532260 000000000 00000 url issn ref Bevacizumab Avastin ref ... and adenocarcinoma with mixed subtypes . ref name MotoiSzoke Bevacizumab may improve some measures ... A, Moore DF, Murren JR, Schiller JH title Phase II study of cisplatin plus etoposide and bevacizumab ... carcinoma variants of adenocarcinoma. Citation needed date December 2010 Bevacizumab is contraindicated ... more details
Encyclopedia
top
